How Digital Pathology Became Altasciences’ Competitive Advantage for Preclinical Studies
HOW DIGITAL PATHOLOGY BECAME ALTASCIENCES’ COMPETITIVE ADVANTAGE FOR PRECLINICAL STUDIES
Dive into the world of digital pathology with Altasciences, a forward-thinking CRO known for its flexible approach to preclinical and clinical pharmacology studies, and whose purpose is to help their customers research and develop potentially life-saving therapeutics faster.
Their VP of Pathology Services, Dr. Wendell Davis, will share why Altasciences made the decision to adopt digital pathology, the challenges they overcame along the way, key lessons his team has learned, and the significant benefits of making the digital leap.
Dr. Davis will be joined by Nathan Buchbinder, Chief Strategy Officer at Proscia. They’ll discuss the digital adoption curve in preclinical drug development, and the industry-wide challenges CROs like Altasciences face in a fast-paced market that demands efficient solutions. Dr. Davis will cover how he aligned the priorities of key stakeholders, and orchestrated people, processes and technology to deploy digital pathology successfully– and deliver consistent, faster, higher quality results to their customers.
Attendees of this webinar will learn
- How to address the specific needs to key stakeholders, including pathologists and scientists, program managers, Q/A, and IT leadership.
- The importance of selecting the right technology for faster study workflows and simplified compliance, and the long-term value of an end-to-end platform.
- Best practices for adopting digital pathology, or evolving your initial digital deployment. Learn how to figure out your starting points, and move forward in a way that best suits the needs of your business.
speakers
Dr. Wendell Davis, DVM, DACVP
Vice President, Pathology, Altasciences
Dr. Wendell Davis joined Altasciences in 2022. He is a nonclinical development professional with extensive experience in toxicologic pathology and a proven track record of building and leading high functioning pathology groups in both the biotechnology and CRO sectors. He is a proven leader with a passion for building pathology capabilities and mentoring pathologists, research, and laboratory scientists. As a study pathologist and peer reviewer, he has experience evaluating small molecules, biologics, oligonucleotide, and an array of RNA therapeutics modalities across a range of preclinical species and routes of administration, in support of both early candidate selection and regulatory filings. Dr. Davis has co-authored over 25 publications, abstracts, and poster presentations. Prior to joining Altasciences, he held management roles in pathology and preclinical safety at Alnylam Pharmaceuticals, Charles River Laboratories, and Biogen Idec. Dr. Davis also maintains an active role in the industry as a member of the Society of Toxicologic Pathology and as a diplomat member of the American College of Veterinary Pathologists.
Nathan Buchbinder is Co-Founder and Chief Strategy Officer at Proscia, a leader in digital and computational pathology, where he sets company strategy and industry-focused initiatives. Under his direction, Proscia’s AI-enabled enterprise pathology platform has become the leading solution driving modernization across life sciences organizations and diagnostic laboratories.
Comments are closed.